Peritransplantation Use of Ruxolitinib in Myelofibrosis-Reference-Cited by-同舟云学术

Peritransplantation Use of Ruxolitinib in Myelofibrosis

Published:2020-12 Issue:12 Volume:26 Page:2177-2180
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Ibrahim Uroosa,Petrone Giulia Eva Maria,Mascarenhas John,Keyzner Alla

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference16 articles.

1. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib;Elli;Front Oncol,2019

2. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses;Verstovsek;J Hematol Oncol,2017

3. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib;Jaekel;Bone Marrow Transplant,2014

4. Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study;Gupta;Biol Blood Marrow Transplant,2019

5. Ruxolitinib for patients with primary or secondary myelofibrosis before allogeneic hematopoietic stem cell transplantation (allo-HSCT): a retrospective study of the Société Française de Greffe de Moëlle et de Thérapie Cellulaire (SFGM-TC);Lebon,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis;Annals of Hematology;2024-03-18

2. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials;Expert Opinion on Emerging Drugs;2021-10-02